These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19671059)

  • 1. Triptolide abrogates oncogene FIP1L1-PDGFRalpha addiction and induces apoptosis in hypereosinophilic syndrome.
    Jin Y; Chen Q; Lu Z; Chen B; Pan J
    Cancer Sci; 2009 Nov; 100(11):2210-7. PubMed ID: 19671059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells.
    Wu Y; Chen C; Sun X; Shi X; Jin B; Ding K; Yeung SC; Pan J
    Clin Cancer Res; 2012 Apr; 18(7):1966-78. PubMed ID: 22447844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.
    Shen Y; Ren X; Ding K; Zhang Z; Wang D; Pan J
    Oncotarget; 2014 Nov; 5(21):10407-20. PubMed ID: 25431951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.
    Lierman E; Folens C; Stover EH; Mentens N; Van Miegroet H; Scheers W; Boogaerts M; Vandenberghe P; Marynen P; Cools J
    Blood; 2006 Aug; 108(4):1374-6. PubMed ID: 16645167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin.
    Jin Y; Ding K; Li H; Xue M; Shi X; Wang C; Pan J
    Mol Cancer; 2014 Jan; 13():17. PubMed ID: 24472312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα.
    Shen Y; Shi X; Pan J
    PLoS One; 2013; 8(8):e73059. PubMed ID: 24009732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.
    Stover EH; Chen J; Lee BH; Cools J; McDowell E; Adelsperger J; Cullen D; Coburn A; Moore SA; Okabe R; Fabbro D; Manley PW; Griffin JD; Gilliland DG
    Blood; 2005 Nov; 106(9):3206-13. PubMed ID: 16030188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.
    Pan J; Quintás-Cardama A; Manshouri T; Giles FJ; Lamb P; Tefferi A; Cortes J; Kantarjian H; Verstovsek S
    Leukemia; 2007 Jul; 21(7):1395-404. PubMed ID: 17495975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
    Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
    Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.
    Baccarani M; Cilloni D; Rondoni M; Ottaviani E; Messa F; Merante S; Tiribelli M; Buccisano F; Testoni N; Gottardi E; de Vivo A; Giugliano E; Iacobucci I; Paolini S; Soverini S; Rosti G; Rancati F; Astolfi C; Pane F; Saglio G; Martinelli G
    Haematologica; 2007 Sep; 92(9):1173-9. PubMed ID: 17666373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.
    Sadovnik I; Lierman E; Peter B; Herrmann H; Suppan V; Stefanzl G; Haas O; Lion T; Pickl W; Cools J; Vandenberghe P; Valent P
    Exp Hematol; 2014 Apr; 42(4):282-293.e4. PubMed ID: 24407160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.
    Lierman E; Michaux L; Beullens E; Pierre P; Marynen P; Cools J; Vandenberghe P
    Leukemia; 2009 May; 23(5):845-51. PubMed ID: 19212337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms for the proliferation of eosinophilic leukemia cells by FIP1L1-PDGFRalpha.
    Ishihara K; Kitamura H; Hiraizumi K; Kaneko M; Takahashi A; Zee O; Seyama T; Hong J; Ohuchi K; Hirasawa N
    Biochem Biophys Res Commun; 2008 Feb; 366(4):1007-11. PubMed ID: 18086564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].
    Li B; Zhang GS; Dai CW; Pei MF
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):448-52. PubMed ID: 15854548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells.
    Fukushima K; Matsumura I; Ezoe S; Tokunaga M; Yasumi M; Satoh Y; Shibayama H; Tanaka H; Iwama A; Kanakura Y
    J Biol Chem; 2009 Mar; 284(12):7719-32. PubMed ID: 19147501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells.
    Verstovsek S; Giles FJ; Quintás-Cardama A; Manshouri T; Huynh L; Manley P; Cortes J; Tefferi A; Kantarjian H
    Leuk Res; 2006 Dec; 30(12):1499-505. PubMed ID: 16682077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib).
    von Bubnoff N; Gorantla SP; Thöne S; Peschel C; Duyster J
    Blood; 2006 Jun; 107(12):4970-1; author reply 4972. PubMed ID: 16754777
    [No Abstract]   [Full Text] [Related]  

  • 18. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.
    Cools J; Stover EH; Boulton CL; Gotlib J; Legare RD; Amaral SM; Curley DP; Duclos N; Rowan R; Kutok JL; Lee BH; Williams IR; Coutre SE; Stone RM; DeAngelo DJ; Marynen P; Manley PW; Meyer T; Fabbro D; Neuberg D; Weisberg E; Griffin JD; Gilliland DG
    Cancer Cell; 2003 May; 3(5):459-69. PubMed ID: 12781364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
    Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU
    Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tyrosine phosphatase SHP2 is required for cell transformation by the receptor tyrosine kinase mutants FIP1L1-PDGFRα and PDGFRα D842V.
    Noël LA; Arts FA; Montano-Almendras CP; Cox L; Gielen O; Toffalini F; Marbehant CY; Cools J; Demoulin JB
    Mol Oncol; 2014 May; 8(3):728-40. PubMed ID: 24618081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.